Revamping the U.S. Drug Safety System: Cleveland Clinic's Steven Nissen, MD, Among Featured Participants at Windhover's FDA/CMS Summit
Posted on: Wednesday, 25 October 2006, 09:01 CDT
The Food and Drug Administration's (FDA) approach to drug safety is headed for significant changes in the wake of several high-profile drug withdrawals, critiques of the advisory committee process, and pending legislation to revamp its review procedures. These changes will have a lasting impact on the companies that develop and market regulated drugs. Steven E. Nissen, M.D., FACC, Vice-Chairman of Cardiology, The Cleveland Clinic Foundation, will headline an in-depth discussion of the changes underway and in consideration for the FDA's drug evaluation and safety assessment procedures at Windhover's FDA/CMS Summit.
The Summit will take place Dec. 4-5 in Washington, DC. Online registration is available at www.windhover.com/fda-cms.
Nissen, a former member of FDA's Cardiovascular and Renal Drugs Advisory Committee and a key figure in the Cleveland Clinic's emergence as a major clinical trials site, is a leading academic advocate for changes in FDA's approach to assessing drug safety. He coauthored an analysis of FDA's review of Bristol-Myers Squibb's Pargluva™ new drug application that coincided with the agency's decision not to approve the drug. Additionally, Nissen participated in the recent Institute of Medicine review of the U.S. drug safety system, calling for randomized trials when safety signals arise and for FDA to "raise the bar" on approval standards for first-in-class drugs.
Dr. Nissen's outside perspective will complement those of top FDA policymakers, including acting Commissioner Andrew von Eschenbach, MD, Deputy Commissioners Janet Woodcock, MD, and Scott Gottlieb, MD, and Center for Drug Evaluation & Research Director Steven Galson, MD.
The summit comes at a watershed point for FDA -- one month after the Congressional elections will usher in a new Congress with an intensified focus on the agency. The FDA/CMS Summit will help pharmaceutical executives identify the issues at stake for the agency and its regulated industry constituents.
A complete agenda and registrations for the summit are available at www.windhover.com/fda-cms.
Who Should Attend?
The FDA/CMS Summit is designed as a unique opportunity for face-to-face dialogues with top policymakers and executives. It is designed for industry executives in all areas of responsibility who want to create successful strategies for dealing with FDA and CMS. Attendees will get practical, real-life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles, and will also be able to benchmark their regulatory strategy against all the major pharmaceutical and biotechnology companies.
Register Now
To register for the summit, contact Alexandria Riley at (203) 838-4401 ext. 113 or ariley@windhover.com; or register on the FDA-CMS Conference website at www.windhover.com/fda-cms.
Sponsors for the FDA/CMS summit are Foley Hoag LLP, Ogilvy Public Relations, the Personalized Medicine Coalition and The RPM Report.
The RPM Report is a unique Windhover publication that examines FDA and CMS from a business perspective, designed to deliver not only the news from FDA and CMS but to tell executives what it all means to their companies. The RPM Report is written for the biopharma CEO, business development director, R&D chief, marketer, reimbursement manager, or public affairs specialist. A complimentary issue is available by clicking here (http://www.windhover.com/ezine/html/fdacms06-SI.htm).
Media sponsors are Business Wire and CanBiotech.
About Windhover Information
Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see www.windhover.com.
Source: Business Wire
Related Articles
- FDA Kicks Controversial Drug Down a Notch
- FDA Authorizes Diabetes Drug for Pregnant Women
- Former FDA & CMS Administrator Dr. Mark McClellan to Share Insights on Coming Changes in DC
- Windhover Information's FDA/CMS Summit for Biopharmaceutical Executives
- Windhover Information's FDA/CMS Summit for BioPharma Executives
- Windhover Information's FDA/CMS Summit for BioPharma Executives: Commercial Success in the Regulatory Environment; Pfizer's Feczko to Address FDA Impact on Drug Development
- FDA Approves New Drug to Treat Chronic Angina
- CMS Administrator Mark McClellan Headlines Windhover Information Inc.'s ``FDA/CMS Summit for BioPharma Executives''
- Drug Companies Rush to Change Cold Medicine
 |
 |
User Comments (0)
RSS Feeds